<DOC>
	<DOC>NCT00668096</DOC>
	<brief_summary>The objective of this study was to evaluate the efficacy and tolerability of the phosphodiesterase type 5 inhibitor (PDE5 inhibitor), vardenafil, in a broad population of subjects with erectile dysfunction of different aetiologies and severity, who have not been previously treated with a PDE5 inhibitor; Efficacy and safety was compared with placebo.</brief_summary>
	<brief_title>A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Males with erectile dysfunction according to the National Institute of Health (NIH) Consensus statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance Heterosexual relationship for more than 6 months Partner willing to complete the TSS Primary hypoactive sexual desire History of myocardial infarction, stroke or lifethreatening arrhythmia within the prior 6 months Nitrate use Other exclusion criteria apply according to the Summary of Product Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>PDE5 inhibitors</keyword>
</DOC>